Using National Registries to Identify Targeted Therapies for Refractory Urticaria

Affiliations

¹ Immunology & Allergy, Hull University Teaching Hospitals NHS Trust, Castle Hill Hospital, Cottingham, United Kingdom, sujoykhan@gmail.com.
² Paediatric Immunology, Allergy & Infectious Diseases, Great North Children's Hospital, Newcastle upon Tyne, United Kingdom.
³ Paediatric Department, Worcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom.
⁴ Department of Paediatrics, Bristol Royal Hospital for Children, Bristol, United Kingdom.
⁵ Department of Allergy, University Hospitals Leicester NHS Trust, Leicester, United Kingdom.
⁶ Department of Allergy and Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
⁷ Institute of Immunology and Immunotherapy and Institute of Clinical Sciences, University of Birmingham, Birmingham, United Kingdom.
⁸ Paediatric Allergy & Immunology, Southampton Children's Hospital, Southampton, United Kingdom.

Comment

Sujoy Khan et al. Int Arch Allergy Immunol. 2021.

. 2021;182(5):459-460.

doi: 10.1159/000514689. Epub 2021 Mar 9.

¹ Immunology & Allergy, Hull University Teaching Hospitals NHS Trust, Castle Hill Hospital, Cottingham, United Kingdom, sujoykhan@gmail.com.
² Paediatric Immunology, Allergy & Infectious Diseases, Great North Children's Hospital, Newcastle upon Tyne, United Kingdom.
³ Paediatric Department, Worcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom.
⁴ Department of Paediatrics, Bristol Royal Hospital for Children, Bristol, United Kingdom.
⁵ Department of Allergy, University Hospitals Leicester NHS Trust, Leicester, United Kingdom.
⁶ Department of Allergy and Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
⁷ Institute of Immunology and Immunotherapy and Institute of Clinical Sciences, University of Birmingham, Birmingham, United Kingdom.
⁸ Paediatric Allergy & Immunology, Southampton Children's Hospital, Southampton, United Kingdom.

No abstract available

Comment on

High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?
Türk M, Yılmaz İ. Türk M, et al. Int Arch Allergy Immunol. 2021;182(5):461-462. doi: 10.1159/000512373. Epub 2020 Dec 15. Int Arch Allergy Immunol. 2021. PMID: 33321510 No abstract available.